Last reviewed · How we verify
AK131
AK131 is a small molecule targeting the CD47/SIRPα axis to modulate the immune system.
AK131 is a small molecule targeting the CD47/SIRPα axis to modulate the immune system. Used for Metastatic solid tumors.
At a glance
| Generic name | AK131 |
|---|---|
| Sponsor | Akeso |
| Drug class | CD47/SIRPα modulator |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AK131 works by binding to CD47, a protein that sends a 'do not eat' signal to macrophages, thereby preventing them from engulfing and destroying cancer cells. This allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Metastatic solid tumors
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Reverse Triple Negative Immune Resistant Breast Cancer (PHASE2)
- A Study of AK131 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK131 CI brief — competitive landscape report
- AK131 updates RSS · CI watch RSS
- Akeso portfolio CI